Invention Grant
![7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors](/docs/US/2021-05-11/US11001596B2/abs.jpg.600x600.jpg)
- Patent Title: 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors
-
Application No.: US16349873Application Date: 2017-12-08
-
Publication No.: US11001596B2Publication Date: 2021-05-11
- Inventor: Renato Alejandro Bauer , Serge Louis Boulet , Timothy Paul Burkholder , Patric James Hahn , Zoran Rankovic
- Applicant: Eli Lilly and Company
- Applicant Address: US IN Indianapolis
- Assignee: Eli Lilly and Company
- Current Assignee: Eli Lilly and Company
- Current Assignee Address: US IN Indianapolis
- Agent Joseph M. Pletcher
- International Application: PCT/US2017/065246 WO 20171208
- International Announcement: WO2018/111707 WO 20180621
- Main IPC: C07D498/04
- IPC: C07D498/04 ; A61P35/02
![7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant IDH1 and IDH2 inhibitors](/abs-image/US/2021/05/11/US11001596B2/abs.jpg.150x150.jpg)
Abstract:
A compound, as defined herein, or pharmaceutical composition containing the compound, for use in treating IDH1 or IDH2 mutant cancer and having the structure: (I).
Public/Granted literature
- US20200079791A1 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AS MUTANT IDH1 AND IDH2 INHIBITORS Public/Granted day:2020-03-12
Information query
